Jacob Worm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacob Worm has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Lars Bendtsen
Department of Neurology, Danish Headache Center University of Copenhagen, Rigshospitalet‐Glostrup Glostrup Denmark
3 shared publicationsPer Rochat
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
2 shared publicationsStine Maarbjerg
Department of Neurology, Danish Headache Center University of Copenhagen, Rigshospitalet‐Glostrup Glostrup Denmark
2 shared publications- Stine Maarbjerg
Danish Headache Center, Department of Neurology, Rigshospitalet - Glostrup, University of Copenhagen, Denmark
2 shared publications - Tone Bruvik Heinskou
Department of Neurology, Neuropathic Pain and CRPS Clinic, Copenhagen University Hospital – Rigshospitalet, Glostrup, Denmark
2 shared publications - Anja Sofie Petersen
Danish Headache Center, Department of Neurology University of Copenhagen, Rigshospitalet‐Glostrup Glostrup Denmark
1 shared publication
Latest Publications
- Open Access
- 16 October 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (10) , 1-11
Five-year prospective outcomes of medical management and microvascular decompression in trigeminal neuralgia
Background: Trigeminal neuralgia is a severe facial pain disorder with major impact on quality of life. Long-term prospective data comparing medical and surgical treatments remain scarce. This study compared 5-year outcomes of medical management and microvascular decompression (MVD) and explored predictors of treatment response. Methods: We conducted a prospective observational cohort study at a national referral center (2012–2019). Consecutive patients with classical or idiopathic trigeminal neuralgia underwent MRI, baseline assessment, and systematic 5-year follow-up. Treatment allocation (medical therapy or MVD) followed clinical evaluation and international guidelines. The primary outcome was categorized as pain-free without medication, pain-free with medication, continued pain without medication, or continued pain with medication. Results: Of 626 eligible patients, 227 completed follow-up (95 MVD, 132 medical). Pain-free without medication was achieved in 59% of MVD patients versus 19% of medically treated [relative risk (RR) 3.03, 95% confidence interval (CI) 1.67–5.50]. Pain-free with medication occurred in 1% after MVD versus 14% of the medical cohort (RR 0.16, 95% CI 0.04–0.69). Continued pain on medication was less frequent after MVD (22% vs 49%; RR 0.44, 95% CI 0.24–0.80). Male sex predicted excellent outcome after MVD (odds ratio 2.60, 95% CI 1.02–6.91). Postoperative hypoesthesia occurred in 23% and hearing impairment in 7%, while 55% of medically treated patients reported side effects. Conclusions: MVD provided superior long-term pain relief, higher rates of medication-free pain freedom, and reduced medication use compared with medical management, supporting earlier surgical consideration in selected patients and emphasizing individualized, guideline-based care.
- 16 October 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (10) , 1-11
Open AccessFive-year prospective outcomes of medical management and microvascular decompression in trigeminal neuralgia
Background: Trigeminal neuralgia is a severe facial pain disorder with major impact on quality of life. Long-term prospective data comparing medical and surgical treatments remain scarce. This study compared 5-year outcomes of medical management and microvascular decompression (MVD) and explored predictors of treatment response. Methods: We conducted a prospective observational cohort study at a national referral center (2012–2019). Consecutive patients with classical or idiopathic trigeminal neuralgia underwent MRI, baseline assessment, and systematic 5-year follow-up. Treatment allocation (medical therapy or MVD) followed clinical evaluation and international guidelines. The primary outcome was categorized as pain-free without medication, pain-free with medication, continued pain without medication, or continued pain with medication. Results: Of 626 eligible patients, 227 completed follow-up (95 MVD, 132 medical). Pain-free without medication was achieved in 59% of MVD patients versus 19% of medically treated [relative risk (RR) 3.03, 95% confidence interval (CI) 1.67–5.50]. Pain-free with medication occurred in 1% after MVD versus 14% of the medical cohort (RR 0.16, 95% CI 0.04–0.69). Continued pain on medication was less frequent after MVD (22% vs 49%; RR 0.44, 95% CI 0.24–0.80). Male sex predicted excellent outcome after MVD (odds ratio 2.60, 95% CI 1.02–6.91). Postoperative hypoesthesia occurred in 23% and hearing impairment in 7%, while 55% of medically treated patients reported side effects. Conclusions: MVD provided superior long-term pain relief, higher rates of medication-free pain freedom, and reduced medication use compared with medical management, supporting earlier surgical consideration in selected patients and emphasizing individualized, guideline-based care.
- Open Access
- 9 February 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (2) , e70053
From Tics to Stabs: Renaming Cluster Tics in Cluster Headache—A Cross‐Sectional Study
Background: Short‐lasting paroxysms of facial pain in patients with cluster headache have traditionally been called “cluster tics.” Mostly described as co‐occurring trigeminal neuralgia, they remain to be explored as an independent phenomenon. We investigated the prevalence of cluster tics in cluster headache, the clinical differentiation from trigeminal neuralgia, and propose a distinct definition and renaming of cluster tics.Methods: We conducted a retrospective, controlled, cross‐sectional study using semi‐structured interviews of patients with cluster headache at the Danish Headache Center. A comparator cohort of patients with trigeminal neuralgia was included from a previous study. We investigated the lifetime prevalence of cluster tics in the cluster headache group and characterized them according to duration, location, pain‐intensity, triggerability, and serial occurrence.Results: We included 424 participants with cluster headache (median age 52 years (IQR: 32–72), male–female ratio 3:2) and 576 participants with trigeminal neuralgia (median age 72 years (IQR: 50–94), male–female ratio 1:3). Cluster tics were reported by 200 (47%) cluster headache participants with higher odds for participants of female sex (OR: 1.94, 95% CI: 1.27–2.96, p = 0.002) and participants with chronic cluster headache (OR: 1.74, 95% CI: 1.15–2.63, p = 0.008). Unlike trigeminal neuralgia, cluster tics were not triggerable (OR: 0.02, 95% CI: 0.01–0.04, p < 2e‐16) and presented with pain restricted to the first trigeminal division.Conclusions: Cluster tics are prevalent in nearly half of patients with cluster headache, associated to female sex and chronic phenotype. Unlike trigeminal neuralgia, cluster tics occur in the orbital region and are largely non‐triggerable. To improve terminology, we propose renaming cluster tics to “cluster stabs.”
- 9 February 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (2) , e70053
Open AccessFrom Tics to Stabs: Renaming Cluster Tics in Cluster Headache—A Cross‐Sectional Study
Background: Short‐lasting paroxysms of facial pain in patients with cluster headache have traditionally been called “cluster tics.” Mostly described as co‐occurring trigeminal neuralgia, they remain to be explored as an independent phenomenon. We investigated the prevalence of cluster tics in cluster headache, the clinical differentiation from trigeminal neuralgia, and propose a distinct definition and renaming of cluster tics.Methods: We conducted a retrospective, controlled, cross‐sectional study using semi‐structured interviews of patients with cluster headache at the Danish Headache Center. A comparator cohort of patients with trigeminal neuralgia was included from a previous study. We investigated the lifetime prevalence of cluster tics in the cluster headache group and characterized them according to duration, location, pain‐intensity, triggerability, and serial occurrence.Results: We included 424 participants with cluster headache (median age 52 years (IQR: 32–72), male–female ratio 3:2) and 576 participants with trigeminal neuralgia (median age 72 years (IQR: 50–94), male–female ratio 1:3). Cluster tics were reported by 200 (47%) cluster headache participants with higher odds for participants of female sex (OR: 1.94, 95% CI: 1.27–2.96, p = 0.002) and participants with chronic cluster headache (OR: 1.74, 95% CI: 1.15–2.63, p = 0.008). Unlike trigeminal neuralgia, cluster tics were not triggerable (OR: 0.02, 95% CI: 0.01–0.04, p < 2e‐16) and presented with pain restricted to the first trigeminal division.Conclusions: Cluster tics are prevalent in nearly half of patients with cluster headache, associated to female sex and chronic phenotype. Unlike trigeminal neuralgia, cluster tics occur in the orbital region and are largely non‐triggerable. To improve terminology, we propose renaming cluster tics to “cluster stabs.”
- 1 October 2024
- Published by Wolters Kluwer Health in Pain
- Vol. 166 (4) , 879-887
Trigeminal neuralgia and its comorbidities: a nationwide disease trajectory study
There is a limited understanding of risk factors and comorbidities in trigeminal neuralgia, a disease characterized by paroxysms of severe unilateral facial pain and a higher incidence in women. We aim to identify temporally associated comorbidities involving trigeminal neuralgia by analyzing nationwide disease trajectories. Using data from 7.2 million unique individuals in the Danish National Patient Register between 1994 and 2018, each individual diagnosed with trigeminal neuralgia was compared with 10,000 matched controls to identify co-occurring diseases. The sequential disease associations were identified in sex-stratified disease trajectories. A Cox-regression analysis investigated whether treatment with carbamazepine or oxcarbazepine, as compared with gabapentin, pregabalin, or lamotrigine, was associated with stroke risk. Finally, we investigated the stroke polygenic risk score and its association with stroke incidence in a subset of genotyped individuals with trigeminal neuralgia. We included 7141 individuals with trigeminal neuralgia (64.2% female, mean age at diagnosis 58.7 years) and identified 18 diseases associated with subsequent trigeminal neuralgia. After diagnosis, trigeminal neuralgia was associated with 9 diseases, including ischemic stroke (relative risk 1.55). Carbamazepine or oxcarbazepine treatment increased the ischemic stroke risk (hazard ratio 1.78; 95% confidence interval 1.47-2.17); however, the polygenic risk of stroke showed no association. In the Danish population, a trigeminal neuralgia diagnosis is temporally associated with 27 diseases revealed in systematic disease trajectories. Trigeminal neuralgia itself and its first-line treatment, but not a stroke polygenic risk score, was associated with an increased risk of ischemic stroke indicating that vascular risk factors should be routinely assessed in individuals with trigeminal neuralgia.
- 1 October 2024
- Published by Wolters Kluwer Health in Pain
- Vol. 166 (4) , 879-887
Trigeminal neuralgia and its comorbidities: a nationwide disease trajectory study
There is a limited understanding of risk factors and comorbidities in trigeminal neuralgia, a disease characterized by paroxysms of severe unilateral facial pain and a higher incidence in women. We aim to identify temporally associated comorbidities involving trigeminal neuralgia by analyzing nationwide disease trajectories. Using data from 7.2 million unique individuals in the Danish National Patient Register between 1994 and 2018, each individual diagnosed with trigeminal neuralgia was compared with 10,000 matched controls to identify co-occurring diseases. The sequential disease associations were identified in sex-stratified disease trajectories. A Cox-regression analysis investigated whether treatment with carbamazepine or oxcarbazepine, as compared with gabapentin, pregabalin, or lamotrigine, was associated with stroke risk. Finally, we investigated the stroke polygenic risk score and its association with stroke incidence in a subset of genotyped individuals with trigeminal neuralgia. We included 7141 individuals with trigeminal neuralgia (64.2% female, mean age at diagnosis 58.7 years) and identified 18 diseases associated with subsequent trigeminal neuralgia. After diagnosis, trigeminal neuralgia was associated with 9 diseases, including ischemic stroke (relative risk 1.55). Carbamazepine or oxcarbazepine treatment increased the ischemic stroke risk (hazard ratio 1.78; 95% confidence interval 1.47-2.17); however, the polygenic risk of stroke showed no association. In the Danish population, a trigeminal neuralgia diagnosis is temporally associated with 27 diseases revealed in systematic disease trajectories. Trigeminal neuralgia itself and its first-line treatment, but not a stroke polygenic risk score, was associated with an increased risk of ischemic stroke indicating that vascular risk factors should be routinely assessed in individuals with trigeminal neuralgia.
- Open Access
- 18 April 2023
- Published by SAGE Publications in Cephalalgia
- Vol. 43 (5)
Efficacy of surgical treatment in patients with trigeminal neuralgia secondary to multiple sclerosis: A prospective study of 18 cases with evaluation of outcome and complications by independent evaluators
Introduction: Medical treatments for trigeminal neuralgia secondary to multiple sclerosis have low efficacy and tolerability and scientific evidence regarding efficacy of neurosurgery is scarce. We aimed to assess neurosurgical outcome and complications in trigeminal neuralgia secondary to multiple sclerosis. Methods: Patients with trigeminal neuralgia secondary to multiple sclerosis who underwent microvascular decompression, glycerol rhizolysis or balloon compression were prospectively and consecutively included from 2012 to 2019. Preoperatively, we systematically obtained clinical characteristics and performed a 3.0 Tesla MRI. Follow-up at three, six and 12 months was performed by independent assessors. Results: We included 18 patients. Of the seven patients treated with microvascular decompression, two patients (29%) had an excellent outcome (both had neurovascular contact with morphological changes), three patients (43%) had a good outcome, one patient (14%) had treatment failure and one patient (14%) had a fatal outcome. Three patients (43%) had major complications. Of 11 patients treated with percutaneous procedures, seven patients (64%) had an excellent or good outcome with major complications in three patients (27%). Conclusion: Percutaneous procedures provided acceptable outcome and complication rates and should be offered to the majority of patients with trigeminal neuralgia secondary to multiple sclerosis who need surgery. Microvascular decompression is less effective and has a higher complication rate in trigeminal neuralgia secondary to multiple sclerosis compared to microvascular decompression in classical and idiopathic trigeminal neuralgia. Microvascular decompression should only be considered in patients with trigeminal neuralgia secondary to multiple sclerosis when they have neurovascular contact with morphological changes.
- 18 April 2023
- Published by SAGE Publications in Cephalalgia
- Vol. 43 (5)
Open AccessEfficacy of surgical treatment in patients with trigeminal neuralgia secondary to multiple sclerosis: A prospective study of 18 cases with evaluation of outcome and complications by independent evaluators
Introduction: Medical treatments for trigeminal neuralgia secondary to multiple sclerosis have low efficacy and tolerability and scientific evidence regarding efficacy of neurosurgery is scarce. We aimed to assess neurosurgical outcome and complications in trigeminal neuralgia secondary to multiple sclerosis. Methods: Patients with trigeminal neuralgia secondary to multiple sclerosis who underwent microvascular decompression, glycerol rhizolysis or balloon compression were prospectively and consecutively included from 2012 to 2019. Preoperatively, we systematically obtained clinical characteristics and performed a 3.0 Tesla MRI. Follow-up at three, six and 12 months was performed by independent assessors. Results: We included 18 patients. Of the seven patients treated with microvascular decompression, two patients (29%) had an excellent outcome (both had neurovascular contact with morphological changes), three patients (43%) had a good outcome, one patient (14%) had treatment failure and one patient (14%) had a fatal outcome. Three patients (43%) had major complications. Of 11 patients treated with percutaneous procedures, seven patients (64%) had an excellent or good outcome with major complications in three patients (27%). Conclusion: Percutaneous procedures provided acceptable outcome and complication rates and should be offered to the majority of patients with trigeminal neuralgia secondary to multiple sclerosis who need surgery. Microvascular decompression is less effective and has a higher complication rate in trigeminal neuralgia secondary to multiple sclerosis compared to microvascular decompression in classical and idiopathic trigeminal neuralgia. Microvascular decompression should only be considered in patients with trigeminal neuralgia secondary to multiple sclerosis when they have neurovascular contact with morphological changes.